ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

IL18

interleukin 18 · also IGIF, IL1F4, IL-1g, IL-18 · Interleukins

6 programs in company-led studies act on IL18, from 4 companies: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
arumakimigNovartisinhibitorphase 273 runningIL1Bthe company's pipeline
aletekitugruleGlaxoSmithKlineinhibitorphase 292 running–ChEMBL
camoteskimabruleApollo Therapeutics–phase 251 running–NCIt
GHZ339Novartisinhibitorphase 211 runningIL13the company's pipeline
BLN-481ruleBeeline Medicinesinhibitorphase 111 running–the studies' text
GSK4528287GlaxoSmithKline–phase 111 runningIL23Athe company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.